Improving Care at Cystic Fibrosis Centers through Quality Improvement

被引:44
作者
Kraynack, Nathan C. [1 ]
McBride, John T. [1 ]
机构
[1] Akron Childrens Hosp, Div Pediat Pulmonol, Akron, OH 44308 USA
关键词
Cystic fibrosis; quality improvement; clinical microsystems; pulmonary exacerbation; PULMONARY EXACERBATIONS;
D O I
10.1055/s-0029-1238913
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Quality improvement (QI) using a clinical microsystems approach provides cystic fibrosis (CF) centers the opportunity to make a significant positive impact on the health of their patients. The availability of center-specific Outcomes data and the support of the Cystic Fibrosis Foundation are important advantages for these quality improvement efforts. This article illustrates how the clinical microsystems methodology can improve care delivery and outcomes by describing the gradual application of quality improvement principles over the past 5 years by the CF team at the Lewis Walker Cystic Fibrosis Center at Akron Children's Hospital in Akron, Ohio. Using the example of a project to improve the pulmonary function of the pediatric patients at our center as a framework, we describe the QI process from the initial team-building phase, through the assessment of care processes, standardization of care, and developing a culture of continuous improvement. We outline how enthusiastic commitment from physician leadership, clinical managers and central administration, the availability of coaches, and an appreciation of the importance of measurement, patient involvement, Communication, and standardization are critical components for successful process improvement.
引用
收藏
页码:547 / 558
页数:12
相关论文
共 15 条
[1]   The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis [J].
Blumer, JL ;
Saiman, L ;
Konstan, MW ;
Melnick, D .
CHEST, 2005, 128 (04) :2336-2346
[2]  
*CYST FIBR FDN, PORTCF WEB PORT
[3]  
*CYST FIBR FDN, 2006, ACT GUID ACC RAT IMP
[4]   Defining an exacerbation of pulmonary disease in cystic fibrosis [J].
Dakin, C ;
Henry, RL ;
Field, P ;
Morton, J .
PEDIATRIC PULMONOLOGY, 2001, 31 (06) :436-442
[5]  
de Koning Henk, 2006, J Healthc Qual, V28, P4
[6]   EFFECT OF AEROSOLIZED RECOMBINANT HUMAN DNASE ON EXACERBATIONS OF RESPIRATORY SYMPTOMS AND ON PULMONARY-FUNCTION IN PATIENTS WITH CYSTIC-FIBROSIS [J].
FUCHS, HJ ;
BOROWITZ, DS ;
CHRISTIANSEN, DH ;
MORRIS, EM ;
NASH, ML ;
RAMSEY, BW ;
ROSENSTEIN, BJ ;
SMITH, AL ;
WOHL, ME .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (10) :637-642
[7]  
KRAYNACK NC, 2008, PEDIATR PULM, V31, P365
[8]  
KRAYNACK NC, 2005, PEDIATR PULM, V28, P302
[9]  
KRAYNACK NC, 2007, PEDIAT PULMONOL S30, V42, P372
[10]  
KRAYNACK NC, 2005, PEDIATR PULM, V28, P303